Telix Pharmaceuticals Targets $1.5B Revenue as ITM Deal Speeds Therapy Push

Key Points

• Telix expects roughly $1 billion in revenue this year and is targeting about $1.5 billion next year, including an anticipated contribution from ITM; it also aims to shift toward earnings growth beginning in 2028.
• The proposed ITM acquisition would add isotope production and lutetium supply, bring Telix’s planned therapeutic launch forward from 2028 to 2027, and is expected to deliver about $50 million in synergies within two years.
• Telix is advancing late-stage programs across prostate, brain and kidney cancers, including a Phase III prostate-cancer therapy trial and kidney-cancer studies; the company expects to have six approved products by this time next year, subject to regulatory approvals.

Telix Pharmaceuticals NASDAQ: TLX outlined its commercial growth strategy, late-stage radiopharmaceutical pipeline and planned integration of ITM at an investor event in Melbourne, with management emphasizing supply-chain control, therapeutic expansion and a target to transition toward earnings growth beginning in 2028.

Managing Director and Group CEO Chris Behrenbruch said Telix expects revenue of roughly $1 billion this year and anticipates finishing at the top end of its maintained guidance. The company is commercially active in 22 countries, operates 45 manufacturing sites globally and has three FDA-approved products.

Behrenbruch said Telix’s precision medicine business is expected to exceed 25% year-over-year growth, supported by a multi-product strategy and potential label expansions. He described radiopharmaceutical commercialization as dependent on tightly integrated manufacturing, isotope supply, distribution and clinical workflows.

Supply chain and ITM transaction

Behrenbruch said Telix’s strategy is centered on a commercial platform, an expanding development pipeline and manufacturing infrastructure designed to support reliable delivery of radioactive medicines. He said the company’s acquisition of RLS helped strengthen U.S. distribution, with RLS growing from Telix’s fifth-largest distributor to its second-largest distributor by dose volume.

The proposed ITM transaction is intended to add isotope production capabilities, including lutetium supply. Behrenbruch said ITM supplies approximately 80% of the world’s lutetium each day to hospitals in 65 countries. Telix expects ITM-11 to accelerate its entry into therapeutic radiopharmaceuticals, bringing its planned commercial therapeutic launch forward from 2028 to 2027.

Group CFO Darren Smith said ITM’s manufacturing business is supported by long-term commercial lutetium-177 supply contracts extending into the 2030s. He said the business is expected to grow at an 18% compound annual rate over the next five years and currently has margins of about 40%. Telix expects about $50 million in synergies across the combined business within two years.

Smith also said Telix’s precision medicine gross margin has improved to 65%, while R&D investment is estimated at 26% of sales, compared with an average of 35% for therapeutic-focused companies cited by the company.

Prostate imaging and therapy programs

Telix highlighted the potential of its BiPASS study to move PSMA-PET imaging earlier in the prostate cancer diagnostic pathway, including before biopsy. Professor Munir Ghesani of Mount Sinai said gallium-based PSMA-PET imaging has substantially improved the detection of prostate cancer compared with conventional CT and bone scans in certain settings.

Dr. Philip Dundee, Director of the Robotic Surgery Fellowship at Royal Melbourne Hospital, said MRI has reduced unnecessary prostate biopsies but is not definitive. He said MRI and PSMA-PET can provide complementary information, with double-negative results potentially identifying men who can safely avoid biopsy.

Professor Louise Emmett, Director of Theranostics and Nuclear Medicine at St Vincent’s Hospital, discussed Telix’s TLX597-Tx small-molecule therapeutic program. She said the OPTIMAL-PSMA study has completed enrollment of 120 patients and is expected to report findings early next year. The study compares dose-intensified treatment with standard dosing in patients with advanced prostate cancer.

Emmett said early work suggests TLX597-Tx has relatively low kidney and salivary-gland radiation exposure compared with other lutetium-based products discussed at the event. She also described the OPTIMAL-e study, which is testing dose intensification and imaging-guided treatment adaptation in patients with earlier metastatic prostate cancer.

Telix is also advancing TLX591-Tx, a PSMA-targeted radioantibody drug conjugate, in the Phase III ProstACT Global trial. Chief Medical Officer David Cade said the trial’s randomized expansion phase is enrolling across multiple countries and has recently received approvals in China, Japan and the United States.

Brain and kidney cancer pipeline

Professor Andrew Scott of the University of Melbourne discussed Telix’s glioblastoma programs, noting that treatment advances in high-grade brain cancer have been limited for about two decades. He said Telix’s PIXCLARA imaging agent received FDA approval in September for assessing suspected recurrent disease after initial treatment.

Scott also discussed TLX101-Tx, an iodine-131-based therapeutic candidate targeting the LAT1 transporter. Telix is studying the program in the Phase III IPAX BrIGHT trial for patients with relapsed glioblastoma and has completed recruitment in the IPAX-2 study evaluating the therapy alongside chemoradiation in newly diagnosed disease.

In kidney cancer, Cade said Telix’s CA9-targeted Zircaix imaging agent is designed to distinguish clear-cell renal cell carcinoma from benign or non-clear-cell renal lesions. The company expects an FDA decision in 2027. Telix is also enrolling its Phase III LUTEON trial of lutetium girentuximab, or TLX250-Tx, in previously treated advanced clear-cell renal cell carcinoma.

Behrenbruch said Telix expects to have six approved products by this time next year, subject to regulatory approvals. He said the company is targeting approximately $1.5 billion in revenue next year, or about AUD 2 billion, including the anticipated contribution from ITM.

About Telix Pharmaceuticals (NASDAQ:TLX)

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company's principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.